BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36681070)

  • 1. Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy?
    Mendes DCC; Filho CMCC; Garcia N; Ricci MD; Soares JM; Carvalho KC; Baracat EC
    Clinics (Sao Paulo); 2023; 78():100155. PubMed ID: 36681070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
    J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of miRNAs Enriched in Extracellular Vesicles Derived from Serum Samples of Breast Cancer Patients.
    Ozawa PMM; Vieira E; Lemos DS; Souza ILM; Zanata SM; Pankievicz VC; Tuleski TR; Souza EM; Wowk PF; Urban CA; Kuroda F; Lima RS; Almeida RC; Gradia DF; Cavalli IJ; Cavalli LR; Malheiros D; Ribeiro EMSF
    Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31963351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
    Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
    Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
    Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
    PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
    Schwarzenbacher D; Klec C; Pasculli B; Cerk S; Rinner B; Karbiener M; Ivan C; Barbano R; Ling H; Wulf-Goldenberg A; Stanzer S; Rinnerthaler G; Stoeger H; Bauernhofer T; Haybaeck J; Hoefler G; Jahn SW; Parrella P; Calin GA; Pichler M
    Breast Cancer Res; 2019 Feb; 21(1):20. PubMed ID: 30709367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of microRNAs in triple-negative breast cancer.
    Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
    Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.
    Calvano Filho CM; Calvano-Mendes DC; Carvalho KC; Maciel GA; Ricci MD; Torres AP; Filassi JR; Baracat EC
    Tumour Biol; 2014 Aug; 35(8):7733-41. PubMed ID: 24810926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer.
    Hamurcu Z; Sener EF; Taheri S; Nalbantoglu U; Kokcu ND; Tahtasakal R; Cınar V; Guler A; Ozkul Y; Dönmez-Altuntas H; Ozpolat B
    Cell Signal; 2021 Jul; 83():109979. PubMed ID: 33744419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection.
    Matamala N; Vargas MT; González-Cámpora R; Miñambres R; Arias JI; Menéndez P; Andrés-León E; Gómez-López G; Yanowsky K; Calvete-Candenas J; Inglada-Pérez L; Martínez-Delgado B; Benítez J
    Clin Chem; 2015 Aug; 61(8):1098-106. PubMed ID: 26056355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
    Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
    Wang B; Li J; Sun M; Sun L; Zhang X
    IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
    Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
    Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
    Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
    Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
    Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
    Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
    Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
    Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
    Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer.
    Zhang K; Wang YY; Xu Y; Zhang L; Zhu J; Si PC; Wang YW; Ma R
    Pathol Res Pract; 2021 Jun; 222():153458. PubMed ID: 33962174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
    Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
    Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.